Charles River Laboratories Intl. (NYSE:CRL) had its target price boosted by Morgan Stanley from $102.00 to $112.00 in a report released on Tuesday morning. Morgan Stanley currently has a hold rating on the medical research company’s stock.

Other equities research analysts also recently issued research reports about the company. ValuEngine upgraded Charles River Laboratories Intl. from a hold rating to a buy rating in a report on Tuesday. Argus boosted their price objective on Charles River Laboratories Intl. from $125.00 to $140.00 and gave the company a buy rating in a report on Monday, August 27th. Raymond James upgraded Charles River Laboratories Intl. from a market perform rating to an outperform rating and set a $140.00 price objective for the company in a report on Thursday, August 23rd. Credit Suisse Group decreased their price objective on Charles River Laboratories Intl. from $129.00 to $121.00 and set a neutral rating for the company in a report on Tuesday, August 21st. Finally, Barclays boosted their price objective on Charles River Laboratories Intl. from $110.00 to $120.00 and gave the company an equal weight rating in a report on Thursday, August 9th. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Charles River Laboratories Intl. currently has a consensus rating of Buy and an average price target of $126.07.

NYSE:CRL opened at $132.28 on Tuesday. The stock has a market capitalization of $6.20 billion, a P/E ratio of 25.10, a price-to-earnings-growth ratio of 1.63 and a beta of 0.65. The company has a current ratio of 1.72, a quick ratio of 1.48 and a debt-to-equity ratio of 1.52. Charles River Laboratories Intl. has a twelve month low of $96.70 and a twelve month high of $132.49.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 8th. The medical research company reported $1.62 EPS for the quarter, beating the Zacks’ consensus estimate of $1.46 by $0.16. The firm had revenue of $585.30 million for the quarter, compared to analyst estimates of $570.65 million. Charles River Laboratories Intl. had a return on equity of 25.26% and a net margin of 6.38%. The business’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same period last year, the firm posted $1.29 earnings per share. equities analysts predict that Charles River Laboratories Intl. will post 5.88 EPS for the current fiscal year.

In related news, CEO James C. Foster sold 5,005 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $110.80, for a total transaction of $554,554.00. Following the transaction, the chief executive officer now owns 296,676 shares of the company’s stock, valued at $32,871,700.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Birgit Girshick sold 3,978 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Tuesday, July 17th. The shares were sold at an average price of $119.90, for a total value of $476,962.20. Following the transaction, the insider now directly owns 18,999 shares in the company, valued at approximately $2,277,980.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,324 shares of company stock worth $4,504,045. 2.10% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the stock. Mackay Shields LLC boosted its position in shares of Charles River Laboratories Intl. by 272.4% during the second quarter. Mackay Shields LLC now owns 46,182 shares of the medical research company’s stock valued at $5,184,000 after buying an additional 33,781 shares during the last quarter. Gamco Investors INC. ET AL boosted its position in shares of Charles River Laboratories Intl. by 40.0% during the first quarter. Gamco Investors INC. ET AL now owns 7,000 shares of the medical research company’s stock valued at $747,000 after buying an additional 2,000 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Charles River Laboratories Intl. by 2.6% during the first quarter. Principal Financial Group Inc. now owns 207,753 shares of the medical research company’s stock valued at $22,176,000 after buying an additional 5,293 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new position in shares of Charles River Laboratories Intl. during the first quarter valued at approximately $13,139,000. Finally, Rhumbline Advisers boosted its position in shares of Charles River Laboratories Intl. by 4.7% during the second quarter. Rhumbline Advisers now owns 106,963 shares of the medical research company’s stock valued at $12,008,000 after buying an additional 4,842 shares during the last quarter. 97.76% of the stock is currently owned by institutional investors.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Investing in Dividend Stocks

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.